<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"
    dtd-version="1.3" xml:lang="en" article-type="research-article">
    <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml"
        tagset-family="jats">
        <restricted-by>pmc</restricted-by>
    </processing-meta>
    <front>
        <journal-meta>
            <journal-id journal-id-type="nlm-ta">Genes (Basel)</journal-id>
            <journal-id journal-id-type="iso-abbrev">Genes (Basel)</journal-id>
            <journal-id journal-id-type="publisher-id">genes</journal-id>
            <journal-title-group>
                <journal-title>Genes</journal-title>
            </journal-title-group>
            <issn pub-type="epub">2073-4425</issn>
            <publisher>
                <publisher-name>MDPI</publisher-name>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="pmid">36360169</article-id>
            <article-id pub-id-type="pmc">PMC9689779</article-id>
            <article-id pub-id-type="doi">10.3390/genes13111932</article-id>
            <article-id pub-id-type="publisher-id">genes-13-01932</article-id>
            <article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Article</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>The Impact of TSC-1 and -2 Mutations on Response to Therapy in
                    Malignant PEComa: A Multicenter Retrospective Analysis</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <contrib-id contrib-id-type="orcid" authenticated="true">
                        https://orcid.org/0000-0001-8559-7739</contrib-id>
                    <name>
                        <surname>Liu</surname>
                        <given-names>Lawrence</given-names>
                    </name>
                    <xref rid="af1-genes-13-01932" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Dehner</surname>
                        <given-names>Carina</given-names>
                    </name>
                    <xref rid="af2-genes-13-01932" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Grandhi</surname>
                        <given-names>Nikhil</given-names>
                    </name>
                    <xref rid="af3-genes-13-01932" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Lyu</surname>
                        <given-names>Yang</given-names>
                    </name>
                    <xref rid="af4-genes-13-01932" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                    <contrib-id contrib-id-type="orcid" authenticated="true">
                        https://orcid.org/0000-0002-8849-2139</contrib-id>
                    <name>
                        <surname>Borcherding</surname>
                        <given-names>Dana C.</given-names>
                    </name>
                    <xref rid="af4-genes-13-01932" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Chrisinger</surname>
                        <given-names>John S. A.</given-names>
                    </name>
                    <xref rid="af2-genes-13-01932" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Zhang</surname>
                        <given-names>Xiao</given-names>
                    </name>
                    <xref rid="af4-genes-13-01932" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Luo</surname>
                        <given-names>Jingqin</given-names>
                    </name>
                    <xref rid="af4-genes-13-01932" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Tao</surname>
                        <given-names>Yu</given-names>
                    </name>
                    <xref rid="af4-genes-13-01932" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Parkes</surname>
                        <given-names>Amanda</given-names>
                    </name>
                    <xref rid="af5-genes-13-01932" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Bui</surname>
                        <given-names>Nam Q.</given-names>
                    </name>
                    <xref rid="af6-genes-13-01932" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Davis</surname>
                        <given-names>Elizabeth J.</given-names>
                    </name>
                    <xref rid="af7-genes-13-01932" ref-type="aff">7</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Milhem</surname>
                        <given-names>Mohammed M.</given-names>
                    </name>
                    <xref rid="af8-genes-13-01932" ref-type="aff">8</xref>
                </contrib>
                <contrib contrib-type="author">
                    <contrib-id contrib-id-type="orcid" authenticated="true">
                        https://orcid.org/0000-0002-1185-5448</contrib-id>
                    <name>
                        <surname>Monga</surname>
                        <given-names>Varun</given-names>
                    </name>
                    <xref rid="af8-genes-13-01932" ref-type="aff">8</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Weiss</surname>
                        <given-names>Mia</given-names>
                    </name>
                    <xref rid="af4-genes-13-01932" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                    <contrib-id contrib-id-type="orcid" authenticated="true">
                        https://orcid.org/0000-0003-4572-6668</contrib-id>
                    <name>
                        <surname>Tine</surname>
                        <given-names>Brian Van</given-names>
                    </name>
                    <xref rid="af4-genes-13-01932" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                    <contrib-id contrib-id-type="orcid" authenticated="true">
                        https://orcid.org/0000-0003-1719-0771</contrib-id>
                    <name>
                        <surname>Hirbe</surname>
                        <given-names>Angela C.</given-names>
                    </name>
                    <xref rid="af4-genes-13-01932" ref-type="aff">4</xref>
                    <xref rid="c1-genes-13-01932" ref-type="corresp">*</xref>
                </contrib>
            </contrib-group>
            <contrib-group>
                <contrib contrib-type="editor">
                    <name>
                        <surname>Di Liegro</surname>
                        <given-names>Italia</given-names>
                    </name>
                    <role>Academic Editor</role>
                </contrib>
            </contrib-group>
            <aff id="af1-genes-13-01932"><label>1</label>City of Hope Comprehensive Cancer Center,
                Duarte, CA 91010, USA</aff>
            <aff id="af2-genes-13-01932"><label>2</label>Department of Pathology and Immunology,
                Washington University School of Medicine, St. Louis, MO 63110, USA</aff>
            <aff id="af3-genes-13-01932"><label>3</label>Department of Medicine, Washington
                University School of Medicine, St. Louis, MO 63110, USA</aff>
            <aff id="af4-genes-13-01932"><label>4</label>Siteman Cancer Center, Washington
                University School of Medicine, St. Louis, MO 63110, USA</aff>
            <aff id="af5-genes-13-01932"><label>5</label>Carbone Cancer Center, University of
                Wisconsin, Madison, WI 53706, USA</aff>
            <aff id="af6-genes-13-01932"><label>6</label>Stanford Cancer Institute, Stanford
                University, Palo Alto, CA 94305, USA</aff>
            <aff id="af7-genes-13-01932"><label>7</label>Ingram Cancer Center, Vanderbilt
                University, Nashville, TN 37232, USA</aff>
            <aff id="af8-genes-13-01932"><label>8</label>Holden Comprehensive Cancer Center,
                University of Iowa, Iowa City, IA 52722, USA</aff>
            <author-notes>
                <corresp id="c1-genes-13-01932"><label>*</label>Correspondence: <email>
                    hirbea@wustl.edu</email></corresp>
            </author-notes>
            <pub-date pub-type="epub">
                <day>24</day>
                <month>10</month>
                <year>2022</year>
            </pub-date>
            <pub-date pub-type="collection">
                <month>11</month>
                <year>2022</year>
            </pub-date>
            <volume>13</volume>
            <issue>11</issue>
            <elocation-id>1932</elocation-id>
            <history>
                <date date-type="received">
                    <day>12</day>
                    <month>9</month>
                    <year>2022</year>
                </date>
                <date date-type="accepted">
                    <day>20</day>
                    <month>10</month>
                    <year>2022</year>
                </date>
            </history>
            <permissions>
                <copyright-statement>&#x000a9; 2022 by the authors.</copyright-statement>
                <copyright-year>2022</copyright-year>
                <license>
                    <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
                        specific-use="textmining" content-type="ccbylicense">
                        https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                    <license-p>Licensee MDPI, Basel, Switzerland. This article is an open access
                        article distributed under the terms and conditions of the Creative Commons
                        Attribution (CC BY) license (<ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by/4.0/">
                        https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
                </license>
            </permissions>
            <abstract>
                <p>Background: Perivascular epithelioid cell neoplasms (PEComas) are a diverse
                    family of mesenchymal tumors with myomelanocytic differentiation that
                    disproportionately affect women and can be associated with tuberous sclerosis
                    (TS). Although mTOR inhibition is widely used as first-line treatment, it is
                    unclear what genomic alterations exist in these tumors and how they influence
                    the response to therapy. Methods: This was a multicenter study conducted at five
                    sites within the US. The data were collected from 1 January 2004 to 31 January
                    2021. We conducted a retrospective analysis to identify PEComa patients with
                    next-generation sequencing (NGS) data and compared outcomes based on mutations.
                    Results: No significant differences in survival were identified between <italic
                        toggle="yes">TSC-1</italic> and <italic toggle="yes">TSC-2</italic> mutated
                    PEComa or <italic toggle="yes">TSC-1</italic>/<italic toggle="yes">-2</italic>
                    versus other mutations. No significant difference was seen in progression-free
                    survival (PFS) after first-line therapy between mTOR inhibition versus other
                    systemic therapies. Conclusions: We were unable to detect differences in
                    survival based on genomic alterations or PFS between mTOR inhibition versus
                    other systemic therapies. Future studies should seek to identify other drivers
                    of <italic toggle="yes">TSC-1/-2</italic> silencing that could predict response
                    to mTOR inhibition.</p>
            </abstract>
            <kwd-group>
                <kwd>PEComa</kwd>
                <kwd>angiomyolipoma</kwd>
                <kwd>lymphangiomyomatosis</kwd>
                <kwd>mTOR inhibitor</kwd>
                <kwd>everolimus</kwd>
                <kwd>sirolimus</kwd>
                <kwd>temsirolimus</kwd>
            </kwd-group>
            <funding-group>
                <funding-statement>This research received no external funding.</funding-statement>
            </funding-group>
        </article-meta>
    </front>
    <body>
        <sec sec-type="intro" id="sec1-genes-13-01932">
            <title>1. Introduction</title>
            <p>Perivascular epithelioid cell neoplasms (PEComas) are mesenchymal tumors with
                myomelanocytic differentiation. This family of neoplasms consists of renal
                angiomyolipoma (RAL), lymphangiomyomatosis (LAM), clear cell &#x0201c;sugar&#x0201d;
                tumors, hepatic angiomyolipoma, PEComa not otherwise specified (PEComa-NOS), and
                others [<xref rid="B1-genes-13-01932" ref-type="bibr">1</xref>,<xref
                    rid="B2-genes-13-01932" ref-type="bibr">2</xref>,<xref rid="B3-genes-13-01932"
                    ref-type="bibr">3</xref>,<xref rid="B4-genes-13-01932" ref-type="bibr">4</xref>,<xref
                    rid="B5-genes-13-01932" ref-type="bibr">5</xref>]. There are only 40&#x02013;80
                cases per year in the United States. In the literature, median overall survival
                (mOS) is typically 60 months [<xref rid="B5-genes-13-01932" ref-type="bibr">5</xref>].
                Women are disproportionately affected by PEComas (70%), with a median age of
                presentation of 46 years and a range from 15&#x02013;100 years [<xref
                    rid="B6-genes-13-01932" ref-type="bibr">6</xref>]. While some PEComa cases are
                associated with tuberous sclerosis (TS), 80% of cases are sporadic. RALs occur in
                80% of patients with tuberous sclerosis, while LAM occurs in 30% of women with TS [<xref
                    rid="B1-genes-13-01932" ref-type="bibr">1</xref>,<xref rid="B4-genes-13-01932"
                    ref-type="bibr">4</xref>,<xref rid="B7-genes-13-01932" ref-type="bibr">7</xref>,<xref
                    rid="B8-genes-13-01932" ref-type="bibr">8</xref>]. These tumors can appear
                almost anywhere anatomically, and there is not a common symptom or sign associated
                with this neoplasm. For RALs, roughly a quarter of patients may experience flank
                pain, and 5% experience hematuria, but the majority will be asymptomatic and
                detected incidentally by imaging [<xref rid="B1-genes-13-01932" ref-type="bibr">1</xref>
                ,<xref rid="B2-genes-13-01932" ref-type="bibr">2</xref>,<xref
                    rid="B4-genes-13-01932" ref-type="bibr">4</xref>,<xref rid="B9-genes-13-01932"
                    ref-type="bibr">9</xref>]. Histologically, their appearance can vary from having
                epithelioid features to spindle cells, and some tumors have even been found to
                express melanin [<xref rid="B1-genes-13-01932" ref-type="bibr">1</xref>,<xref
                    rid="B2-genes-13-01932" ref-type="bibr">2</xref>,<xref rid="B3-genes-13-01932"
                    ref-type="bibr">3</xref>,<xref rid="B4-genes-13-01932" ref-type="bibr">4</xref>].
                The diagnosis is made by observation of combined smooth muscle and melanocytic
                differentiation, supported by positive staining for Melan A, HMB-45, MITF, and SMA.
                A subset is positive for TFE3. Occasionally, these tumors will show positivity for
                S100 protein, caldesmon, desmin, estrogen receptor, and progesterone receptor [<xref
                    rid="B1-genes-13-01932" ref-type="bibr">1</xref>,<xref rid="B3-genes-13-01932"
                    ref-type="bibr">3</xref>,<xref rid="B4-genes-13-01932" ref-type="bibr">4</xref>
                ].</p>
            <p>The majority of PEComas have a loss of function (LOF) of <italic toggle="yes">TSC-1</italic>
                or <italic toggle="yes">-2</italic> genes (commonly <italic toggle="yes">TSC-2</italic>
                LOF), leading to increased mTOR pathway activation. Therefore, TS patients are most
                predisposed to PEComa family tumors. A minority of tumors harbor rearrangements of
                the <italic toggle="yes">TFE3 (Xp11)</italic> gene locus, which leads to downstream
                activation of mTOR and other cancer promoting pathways [<xref
                    rid="B1-genes-13-01932" ref-type="bibr">1</xref>,<xref rid="B3-genes-13-01932"
                    ref-type="bibr">3</xref>,<xref rid="B4-genes-13-01932" ref-type="bibr">4</xref>,<xref
                    rid="B9-genes-13-01932" ref-type="bibr">9</xref>,<xref rid="B10-genes-13-01932"
                    ref-type="bibr">10</xref>,<xref rid="B11-genes-13-01932" ref-type="bibr">11</xref>
                ,<xref rid="B12-genes-13-01932" ref-type="bibr">12</xref>,<xref
                    rid="B13-genes-13-01932" ref-type="bibr">13</xref>].</p>
            <p>Management involves surgery, radiation, and/or systemic therapy, depending on the
                tumor type, location, invasion, and spread [<xref rid="B4-genes-13-01932"
                    ref-type="bibr">4</xref>,<xref rid="B7-genes-13-01932" ref-type="bibr">7</xref>,<xref
                    rid="B10-genes-13-01932" ref-type="bibr">10</xref>,<xref
                    rid="B12-genes-13-01932" ref-type="bibr">12</xref>,<xref
                    rid="B13-genes-13-01932" ref-type="bibr">13</xref>,<xref
                    rid="B14-genes-13-01932" ref-type="bibr">14</xref>] Given that the vast majority
                of PEComas are driven by mTOR hyper-activation, the widely agreed upon systemic
                therapy is mTOR inhibition via everolimus, sirolimus, or temsirolimus [<xref
                    rid="B7-genes-13-01932" ref-type="bibr">7</xref>]. Bissler et al. performed a
                randomized double-blind placebo-controlled trial evaluating everolimus in patients
                with RAL associated with TS or sporadic LAM [<xref rid="B7-genes-13-01932"
                    ref-type="bibr">7</xref>,<xref rid="B8-genes-13-01932" ref-type="bibr">8</xref>].
                Significant activity was observed, with a 54% overall response rate (ORR) at roughly
                29 months [<xref rid="B7-genes-13-01932" ref-type="bibr">7</xref>]. Follow-up of
                these patients found that for those who had a response to everolimus, tumor growth
                was observed after cessation of therapy [<xref rid="B8-genes-13-01932"
                    ref-type="bibr">8</xref>]. Additionally, randomized controlled trials (RCTs)
                utilizing sirolimus in RAL and LAM showed very similar results and ORRs
                (40&#x02013;50%) [<xref rid="B15-genes-13-01932" ref-type="bibr">15</xref>,<xref
                    rid="B16-genes-13-01932" ref-type="bibr">16</xref>,<xref
                    rid="B17-genes-13-01932" ref-type="bibr">17</xref>]. These studies of everolimus
                and sirolimus along with numerous case reports demonstrate a very good safety
                profile of mTOR inhibition with relatively low rates of adverse events [<xref
                    rid="B4-genes-13-01932" ref-type="bibr">4</xref>,<xref rid="B7-genes-13-01932"
                    ref-type="bibr">7</xref>,<xref rid="B9-genes-13-01932" ref-type="bibr">9</xref>,<xref
                    rid="B10-genes-13-01932" ref-type="bibr">10</xref>,<xref
                    rid="B11-genes-13-01932" ref-type="bibr">11</xref>,<xref
                    rid="B13-genes-13-01932" ref-type="bibr">13</xref>,<xref
                    rid="B15-genes-13-01932" ref-type="bibr">15</xref>]. The recent AMPECT trial
                investigated the efficacy and safety profile of ABI-009, albumin-bound sirolimus, in
                the treatment of malignant PEComa and demonstrated an ORR of 39%, median
                progression-free survival (mPFS) of 10.6 months, and a mOS of 40.6 months [<xref
                    rid="B13-genes-13-01932" ref-type="bibr">13</xref>]. A study by Sanfilippo et
                al. reported the efficacy of various systemic therapies against PEComas: gemcitabine
                (ORR 20%, with mPFS of 3.4 months), anthracyclines (ORR 13%, with mPFS of 3.2
                months), and antiangiogenic agents (ORR 8.3%, with mPFS of 5.4 months); mTOR
                inhibition was still shown to be the most effective (ORR of 41%, with a mPFS of 9
                months) [<xref rid="B14-genes-13-01932" ref-type="bibr">14</xref>]. However, a large
                genomic analysis of these tumors has not been performed. Thus, it is unclear what
                other genomic alterations may exist in these tumors and how they influence the
                response to first-line mTOR inhibition.</p>
        </sec>
        <sec id="sec2-genes-13-01932">
            <title>2. Materials and Methods</title>
            <p>We conducted a retrospective analysis to identify PEComa patients with
                next-generation sequencing (NGS) data and compared outcomes based on mutations. This
                was a multicenter study conducted at five sites within the US: Washington University
                in St. Louis, the University of Wisconsin, the University of Iowa, Stanford
                University, and Vanderbilt University. The data was collected from surgical
                pathology reports from 1 January 2004 to 31 January 2021. Forty-nine patients with
                surgical pathology reports and chart data were identified across the participating
                sites.</p>
            <p>Data from pathology reports were collected and stored in the RedCap database.
                Malignant PEComa was defined as pathology demonstrating two or more of the
                following: primary tumor &#x0003e; 5 cm, infiltrative, high nuclear grade and
                cellularity, mitotic rate &#x02265; 1/50 high power field, necrosis, vascular
                invasion [<xref rid="B18-genes-13-01932" ref-type="bibr">18</xref>]. In addition to
                collecting data on malignant criteria, we also collected data on mutational data
                from NGS, surgery, radiation therapy, systemic therapy, response, metastatic
                disease, time to progression after each treatment line, and survival time. A flow
                chart demonstrating patient accrual is included in the <xref
                    rid="app1-genes-13-01932" ref-type="app">supplementary materials</xref>. A table
                with pathology information of each patient was included in the <xref
                    rid="app1-genes-13-01932" ref-type="app">supplementary materials</xref>.</p>
            <p>Progression-free survival (PFS) was defined as the date of diagnosis to date of
                progression or death or last imaging scan. Overall survival (OS) was defined as the
                date of diagnosis to date of death or last follow-up. PFS and OS were thresholded at
                12 and 50 months, respectively. ORR was defined as partial response (PR) or complete
                response (CR). Clinical benefit rate (CBR) was defined as stable disease, PR, or CR.
                GraphPad Prism 9.1.1 software sourced from Washington University in St. Louis, MO,
                US was used for statistical analyses. Empirical survival probability was estimated
                via Kaplan&#x02013;Meier method and differences estimated via log-rank test.</p>
        </sec>
        <sec sec-type="results" id="sec3-genes-13-01932">
            <title>3. Results</title>
            <p>The patient population was primarily female (72%), and tumor type was mostly PEComas
                other than RAL (68%). Primary tumor location was largely uterine (24%) or
                retroperitoneal/kidney (26%). The majority of patients were treated with surgical
                resection initially (94%), and 32% experienced local recurrence (<xref
                    rid="genes-13-01932-t001" ref-type="table">Table 1</xref><bold>)</bold>. For <italic
                    toggle="yes">TSC-1</italic> or <italic toggle="yes">TSC-2</italic> mutated
                PEComa treated with mTOR inhibition as first-line therapy, the ORR was 25% and CBR
                was 75% compared to 33% and 66%, respectively, for PEComa without the <italic
                    toggle="yes">TSC-1</italic> or <italic toggle="yes">-2</italic> mutations also
                treated with mTOR inhibition (<xref rid="genes-13-01932-t002" ref-type="table">Table
                2</xref>). There was a non-statistically significant trend towards improved OS in <italic
                    toggle="yes">TSC-2</italic> mutated PEComa vs. <italic toggle="yes">TSC-1</italic>
                (<xref rid="genes-13-01932-f001" ref-type="fig">Figure 1</xref>). Patients with <italic
                    toggle="yes">TSC-1</italic> or <italic toggle="yes">-2</italic> mutated tumors
                had an initial trend towards improved OS compared other mutations, which disappeared
                at 50 months (<xref rid="genes-13-01932-f002" ref-type="fig">Figure 2</xref>).
                Patients treated with first-line mTOR inhibition (regardless of mutational status)
                versus other systemic therapy had an initial trend towards improved PFS, which
                disappeared at 12 months (<xref rid="genes-13-01932-f003" ref-type="fig">Figure 3</xref>
                ).</p>
        </sec>
        <sec sec-type="discussion" id="sec4-genes-13-01932">
            <title>4. Discussion</title>
            <p>Although there are only 40&#x02013;80 cases of PEComa per year, they are associated
                with a median OS of 60 months [<xref rid="B1-genes-13-01932" ref-type="bibr">1</xref>
                ,<xref rid="B2-genes-13-01932" ref-type="bibr">2</xref>,<xref
                    rid="B3-genes-13-01932" ref-type="bibr">3</xref>,<xref rid="B4-genes-13-01932"
                    ref-type="bibr">4</xref>,<xref rid="B5-genes-13-01932" ref-type="bibr">5</xref>].
                Additionally, 80% of TS patients develop RALs, and while most are benign, there is a
                risk of malignant transformation. Thus far, upfront mTOR inhibition has provided the
                best results, with the AMPECT trial recently reporting an ORR of 39%, a mPFS of 10.6
                months, and a mOS of 40.6 months [<xref rid="B13-genes-13-01932" ref-type="bibr">13</xref>].
                However, it is unclear what other genomic alterations may exist in these tumors and
                how they influence the response to first-line mTOR inhibition.</p>
            <p>We sought to identify any differences in survival and progression between <italic
                    toggle="yes">TSC-1</italic> or <italic toggle="yes">-2</italic> mutation versus
                other mutations. First, we demonstrated that there was no statistically significant
                difference in survival based on <italic toggle="yes">TSC-1</italic> versus <italic
                    toggle="yes">TSC-2</italic> mutational status. There were only two patients with <italic
                    toggle="yes">TSC-1</italic> mutations, which limits our ability to see a
                difference in response rates between <italic toggle="yes">TSC-1</italic> and <italic
                    toggle="yes">TSC-2</italic>. Second, there was no significant difference in
                survival for <italic toggle="yes">TSC-1</italic> or <italic toggle="yes">TSC-2</italic>
                compared to other mutations. Our ORR for first-line mTOR inhibition (25% in <italic
                    toggle="yes">TSC-1</italic> or <italic toggle="yes">TSC-2</italic> and 33.3% in
                other mutations) was lower in comparison to that of the AMPECT trial (39%) [<xref
                    rid="B13-genes-13-01932" ref-type="bibr">13</xref>]. This suggests that there is
                a benefit to nab-sirolimus over the oral mTOR inhibitors, potentially due to the
                fact that the oral drugs can have variable absorption and incomplete target
                suppression. There were six patients with <italic toggle="yes">TSC-1</italic> and <italic
                    toggle="yes">TSC-2</italic> mutations that were treated with other systemic
                therapies in the first-line setting. It is possible that exclusion of these patients
                led to worse ORR. Third, we did not find a significant difference in PFS1 with mTORi
                versus other therapy. However, most patients received mTOR inhibition and there were
                too few patients who received chemotherapy or immunotherapy first line for us to
                make any statistically significant conclusions.</p>
            <p>The limitations of our study include the retrospective nature and the small sample
                size. Additionally, whole-exome sequencing was utilized as opposed to whole-genome
                sequencing, so intronic splice mutations or copy number changes would not have been
                detected. Future studies should seek to identify other drivers or mechanisms of <italic
                    toggle="yes">TSC-1/-2</italic> silencing that could predict response to therapy.
                Additionally, the identification of TFE3 translocations may be crucial as predictors
                of the theoretical ineffectiveness of mTOR inhibition [<xref
                    rid="B19-genes-13-01932" ref-type="bibr">19</xref>]. Additionally, novel
                mutations could be drivers of this rare cancer, as demonstrated in this presentation
                of cutaneous PEComa [<xref rid="B20-genes-13-01932" ref-type="bibr">20</xref>].
                Identification of such mutations could provide targets for future therapies. Our
                understanding of the behavior and biology of rare cancers such as PEComa is possible
                with collaborations within sarcoma centers.</p>
        </sec>
    </body>
    <back>
        <ack>
            <title>Acknowledgments</title>
            <p>This work was supported by Oncology Division funds at Washington University in STL
                and the Midwest Trials Sarcoma Partnership.</p>
        </ack>
        <fn-group>
            <fn>
                <p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to
                    jurisdictional claims in published maps and institutional affiliations.</p>
            </fn>
        </fn-group>
        <app-group>
            <app id="app1-genes-13-01932">
                <title>Supplementary Materials</title>
                <p>The following supporting information can be downloaded at: <uri
                        xlink:href="https://www.mdpi.com/article/10.3390/genes13111932/s1">
                    https://www.mdpi.com/article/10.3390/genes13111932/s1</uri>, Figure S1: Flow
                    Diagram, Table S1: Patient Characteristics.</p>
                <supplementary-material id="genes-13-01932-s001" position="float"
                    content-type="local-data">
                    <media xlink:href="genes-13-01932-s001.zip">
                        <caption>
                            <p>Click here for additional data file.</p>
                        </caption>
                    </media>
                </supplementary-material>
            </app>
        </app-group>
        <notes>
            <title>Author Contributions</title>
            <p>Conceptualization: A.C.H., L.L., C.D. and J.S.A.C.; methodology: A.C.H., L.L., C.D.,
                J.L. and X.Z.; pathology support and mutational analysis: C.D., J.S.A.C. and Y.L.;
                data entry and collection: L.L., C.D., D.C.B., Y.T., A.P., N.Q.B., E.J.D., V.M. and
                M.M.M.; data analysis: L.L., M.W. and B.V.T.; manuscript writing: L.L., C.D. and
                N.G.; manuscript review and editing: all authors; supervision: A.C.H.; funding
                acquisition: A.C.H. All authors have read and agreed to the published version of the
                manuscript.</p>
        </notes>
        <notes>
            <title>Institutional Review Board Statement</title>
            <p>All human tumor samples were collected under an IRB approved protocol 201203042 and
                appropriate consent was obtained from patients.</p>
        </notes>
        <notes>
            <title>Informed Consent Statement</title>
            <p>Not applicable.</p>
        </notes>
        <notes notes-type="data-availability">
            <title>Data Availability Statement</title>
            <p>Not applicable.</p>
        </notes>
        <notes notes-type="COI-statement">
            <title>Conflicts of Interest</title>
            <p>L.L. has no conflict of interest. C.D. has no conflict of interest. NG has no
                conflict of interest. Y.L. has no conflict of interest. X.Z. has no conflict of
                interest. Y.T. has no conflict of interest. M.W. has no conflict of interest. BVT
                received consulting/speaker fees/attended advisory board meetings from Epizyme,
                ADRx, Ayala Pharm, Cytokinetics Inc., Bayer, Daiichi Sankyo, EcoR1, Targeted
                Oncology, Adaptimmune Limited, Intellisphere LLC., Apexigen, Inc., Deciphera Pharm.,
                PTC Therapuetics, and Boehringer Ingelheim and has received research grants from
                Pfizer, Merck, Tracon Pharm, and GSK and serves on the Polaris board. E.J.D.
                receives institutional research support from Incyte, BMS, Top Alliance Biosciences,
                Actuate, BioAtla, Cornerstone, Karyopharm, and Inhibrix. E.J.D. receives
                consulting/speaker&#x02019;s fees from MJH Life Sciences, Aadi, and Deciphera.
                A.C.H. has served as a consultant for Springworks Therapeutics and Astrazenica and
                has received research funds from Tango therapeutics. J.S.A.C. has no conflict of
                interest. D.C.B. has no conflict of interest. M.M.M. has served on the
                consulting/advisory boards for Blueprints Medicine, Immunocore, Amgen, Trieza, Array
                Biopharma, Biontech, and Novartis and is a member of the Exicure executive steering
                committee. V.M. served on the advisory board of Forma Therapeutics and Astex
                Pharmaceuticals and receives institutional research support from Prelude
                Therapeutics, GSK, Hutchison Pharma, and Amgen. N.B. has no conflict of interest.
                A.P. currently works for Amgen but was working at the University of Wisconsin during
                this study.</p>
        </notes>
        <ref-list>
            <title>References</title>
            <ref id="B1-genes-13-01932">
                <label>1.</label>
                <element-citation publication-type="journal">
                    <person-group person-group-type="author">\n<name>
                            <surname>Haiges</surname>
                            <given-names>D.</given-names>
                        </name>\n<name>
                            <surname>Kurz</surname>
                            <given-names>P.</given-names>
                        </name>\n<name>
                            <surname>Laaff</surname>
                            <given-names>H.</given-names>
                        </name>\n<name>
                            <surname>Meiss</surname>
                            <given-names>F.</given-names>
                        </name>\n<name>
                            <surname>Kutzner</surname>
                            <given-names>H.</given-names>
                        </name>\n<name>
                            <surname>Technau-Hafsi</surname>
                            <given-names>K.</given-names>
                        </name>\n</person-group>
                    <article-title>Malignant PEComa</article-title>
                    <source>J. Cutan. Pathol.</source>
                    <year>2018</year>
                    <volume>45</volume>
                    <fpage>84</fpage>
                    <lpage>89</lpage>
                    <pub-id pub-id-type="doi">10.1111/cup.13061</pub-id>
                    <pub-id pub-id-type="pmid">29044701</pub-id>
                </element-citation>
            </ref>
            <ref id="B2-genes-13-01932">
                <label>2.</label>
                <element-citation publication-type="journal">
                    <person-group person-group-type="author">\n<name>
                            <surname>Hu&#x0013e;ov&#x000e1;</surname>
                            <given-names>S.</given-names>
                        </name>\n<name>
                            <surname>Sy&#x0010d;ov&#x000e1;-Mil&#x000e1;</surname>
                            <given-names>Z.</given-names>
                        </name>\n<name>
                            <surname>Mac&#x000e1;k</surname>
                            <given-names>D.</given-names>
                        </name>\n<name>
                            <surname>Janega</surname>
                            <given-names>P.</given-names>
                        </name>\n<name>
                            <surname>Chovanec</surname>
                            <given-names>M.</given-names>
                        </name>\n<name>
                            <surname>Mardiak</surname>
                            <given-names>J.</given-names>
                        </name>\n<name>
                            <surname>Mego</surname>
                            <given-names>M.</given-names>
                        </name>\n</person-group>
                    <article-title>Diagnostic Challenges and Extraordinary Treatment Response in
                        Rare Malignant PEComa Tumor of the Kidney</article-title>
                    <source>Klin. Onkol.</source>
                    <year>2018</year>
                    <volume>31</volume>
                    <fpage>448</fpage>
                    <lpage>452</lpage>
                    <pub-id pub-id-type="doi">10.14735/amko2018448</pub-id>
                    <pub-id pub-id-type="pmid">30545225</pub-id>
                </element-citation>
            </ref>
            <ref id="B3-genes-13-01932">
                <label>3.</label>
                <element-citation publication-type="journal">
                    <person-group person-group-type="author">\n<name>
                            <surname>Thway</surname>
                            <given-names>K.</given-names>
                        </name>\n<name>
                            <surname>Fisher</surname>
                            <given-names>C.</given-names>
                        </name>\n</person-group>
                    <article-title>PEComa: Morphology and genetics of a complex tumor family</article-title>
                    <source>Ann. Diagn. Pathol.</source>
                    <year>2015</year>
                    <volume>19</volume>
                    <fpage>359</fpage>
                    <lpage>368</lpage>
                    <pub-id pub-id-type="doi">10.1016/j.anndiagpath.2015.06.003</pub-id>
                    <pub-id pub-id-type="pmid">26144278</pub-id>
                </element-citation>
            </ref>
            <ref id="B4-genes-13-01932">
                <label>4.</label>
                <element-citation publication-type="journal">
                    <person-group person-group-type="author">\n<name>
                            <surname>Utpatel</surname>
                            <given-names>K.</given-names>
                        </name>\n<name>
                            <surname>Calvisi</surname>
                            <given-names>D.F.</given-names>
                        </name>\n<name>
                            <surname>K&#x000f6;hler</surname>
                            <given-names>G.</given-names>
                        </name>\n<name>
                            <surname>K&#x000fc;hnel</surname>
                            <given-names>T.</given-names>
                        </name>\n<name>
                            <surname>Niesel</surname>
                            <given-names>A.</given-names>
                        </name>\n<name>
                            <surname>Verloh</surname>
                            <given-names>N.</given-names>
                        </name>\n<name>
                            <surname>Vogelhuber</surname>
                            <given-names>M.</given-names>
                        </name>\n<name>
                            <surname>Neu</surname>
                            <given-names>R.</given-names>
                        </name>\n<name>
                            <surname>Hosten</surname>
                            <given-names>N.</given-names>
                        </name>\n<name>
                            <surname>Schildhaus</surname>
                            <given-names>H.-U.</given-names>
                        </name>\n<etal />
                        \n</person-group>
                    <article-title>Complexity of PEComas: Diagnostic approach, molecular background,
                        clinical management</article-title>
                    <source>Pathologe</source>
                    <year>2019</year>
                    <volume>41</volume>
                    <fpage>9</fpage>
                    <lpage>19</lpage>
                    <pub-id pub-id-type="doi">10.1007/s00292-019-0612-5</pub-id>
                    <pub-id pub-id-type="pmid">31309284</pub-id>
                </element-citation>
            </ref>
            <ref id="B5-genes-13-01932">
                <label>5.</label>
                <element-citation publication-type="journal">
                    <person-group person-group-type="author">\n<name>
                            <surname>Bourgmayer</surname>
                            <given-names>A.</given-names>
                        </name>\n<name>
                            <surname>Nannini</surname>
                            <given-names>S.</given-names>
                        </name>\n<name>
                            <surname>Bonjean</surname>
                            <given-names>P.</given-names>
                        </name>\n<name>
                            <surname>Kurtz</surname>
                            <given-names>J.-E.</given-names>
                        </name>\n<name>
                            <surname>Malouf</surname>
                            <given-names>G.G.</given-names>
                        </name>\n<name>
                            <surname>Gantzer</surname>
                            <given-names>J.</given-names>
                        </name>\n</person-group>
                    <article-title>Natural History and Treatment Strategies of Advanced PEComas: A
                        Systematic Review</article-title>
                    <source>Cancers</source>
                    <year>2021</year>
                    <volume>13</volume>
                    <elocation-id>5227</elocation-id>
                    <pub-id pub-id-type="doi">10.3390/cancers13205227</pub-id>
                    <pub-id pub-id-type="pmid">34680376</pub-id>
                </element-citation>
            </ref>
            <ref id="B6-genes-13-01932">
                <label>6.</label>
                <element-citation publication-type="webpage">
                    <person-group person-group-type="author">\n<name>
                            <surname>Shankar</surname>
                            <given-names>V.</given-names>
                        </name>\n</person-group>
                    <article-title>Perivascular Epithelioid Cell</article-title>
                    <year>2019</year>
                    <comment>Available online: <ext-link
                            xlink:href="http://www.pathologyoutlines.com/topic/softtissuepecgeneral.html"
                            ext-link-type="uri">
                        http://www.pathologyoutlines.com/topic/softtissuepecgeneral.html</ext-link></comment>
                    <date-in-citation content-type="access-date" iso-8601-date="2022-10-01">(accessed
                        on 1 October 2022)</date-in-citation>
                </element-citation>
            </ref>
            <ref id="B7-genes-13-01932">
                <label>7.</label>
                <element-citation publication-type="journal">
                    <person-group person-group-type="author">\n<name>
                            <surname>Bissler</surname>
                            <given-names>J.J.</given-names>
                        </name>\n<name>
                            <surname>Kingswood</surname>
                            <given-names>J.C.</given-names>
                        </name>\n<name>
                            <surname>Radzikowska</surname>
                            <given-names>E.</given-names>
                        </name>\n<name>
                            <surname>Zonnenberg</surname>
                            <given-names>B.A.</given-names>
                        </name>\n<name>
                            <surname>Frost</surname>
                            <given-names>M.</given-names>
                        </name>\n<name>
                            <surname>Belousova</surname>
                            <given-names>E.</given-names>
                        </name>\n<name>
                            <surname>Sauter</surname>
                            <given-names>M.</given-names>
                        </name>\n<name>
                            <surname>Nonomura</surname>
                            <given-names>N.</given-names>
                        </name>\n<name>
                            <surname>Brakemeier</surname>
                            <given-names>S.</given-names>
                        </name>\n<name>
                            <surname>de Vries</surname>
                            <given-names>P.J.</given-names>
                        </name>\n<etal />
                        \n</person-group>
                    <article-title>Everolimus for renal angiomyolipoma in patients with tuberous
                        sclerosis complex or sporadic lymphangioleiomyomatosis: Extension of a
                        randomized controlled trial</article-title>
                    <source>Nephrol. Dial. Transplant.</source>
                    <year>2016</year>
                    <volume>31</volume>
                    <fpage>111</fpage>
                    <lpage>119</lpage>
                    <pub-id pub-id-type="doi">10.1093/ndt/gfv249</pub-id>
                    <pub-id pub-id-type="pmid">26156073</pub-id>
                </element-citation>
            </ref>
            <ref id="B8-genes-13-01932">
                <label>8.</label>
                <element-citation publication-type="journal">
                    <person-group person-group-type="author">\n<name>
                            <surname>Bissler</surname>
                            <given-names>J.J.</given-names>
                        </name>\n<name>
                            <surname>Nonomura</surname>
                            <given-names>N.</given-names>
                        </name>\n<name>
                            <surname>Budde</surname>
                            <given-names>K.</given-names>
                        </name>\n<name>
                            <surname>Zonnenberg</surname>
                            <given-names>B.A.</given-names>
                        </name>\n<name>
                            <surname>Fischereder</surname>
                            <given-names>M.</given-names>
                        </name>\n<name>
                            <surname>Voi</surname>
                            <given-names>M.</given-names>
                        </name>\n<name>
                            <surname>Louveau</surname>
                            <given-names>A.-L.</given-names>
                        </name>\n<name>
                            <surname>Herbst</surname>
                            <given-names>F.</given-names>
                        </name>\n<name>
                            <surname>Bebin</surname>
                            <given-names>E.M.</given-names>
                        </name>\n<name>
                            <surname>Curatolo</surname>
                            <given-names>P.</given-names>
                        </name>\n<etal />\n</person-group>
                    <article-title>Angiomyolipoma rebound tumor growth after discontinuation of
                        everolimus in patients with tuberous sclerosis complex or sporadic
                        lymphangioleiomyomatosis</article-title>
                    <source>PLoS ONE</source>
                    <year>2018</year>
                    <volume>13</volume>
                    <elocation-id>e0201005</elocation-id>
                    <pub-id pub-id-type="doi">10.1371/journal.pone.0201005</pub-id>
                    <pub-id pub-id-type="pmid">30192751</pub-id>
                </element-citation>
            </ref>
            <ref id="B9-genes-13-01932">
                <label>9.</label>
                <element-citation publication-type="journal">
                    <person-group person-group-type="author">\n<name>
                            <surname>Rutkowski</surname>
                            <given-names>P.L.</given-names>
                        </name>\n<name>
                            <surname>Mullen</surname>
                            <given-names>J.T.</given-names>
                        </name>\n</person-group>
                    <article-title>Management of the &#x0201c;Other&#x0201d; retroperitoneal
                        sarcomas</article-title>
                    <source>J. Surg. Oncol.</source>
                    <year>2018</year>
                    <volume>117</volume>
                    <fpage>79</fpage>
                    <lpage>86</lpage>
                    <pub-id pub-id-type="doi">10.1002/jso.24893</pub-id>
                    <pub-id pub-id-type="pmid">29127695</pub-id>
                </element-citation>
            </ref>
            <ref id="B10-genes-13-01932">
                <label>10.</label>
                <element-citation publication-type="journal">
                    <person-group person-group-type="author">\n<name>
                            <surname>Benson</surname>
                            <given-names>C.</given-names>
                        </name>\n<name>
                            <surname>Vitfell-Rasmussen</surname>
                            <given-names>J.</given-names>
                        </name>\n<name>
                            <surname>Maruzzo</surname>
                            <given-names>M.</given-names>
                        </name>\n<name>
                            <surname>Fisher</surname>
                            <given-names>C.</given-names>
                        </name>\n<name>
                            <surname>Tunariu</surname>
                            <given-names>N.</given-names>
                        </name>\n<name>
                            <surname>Mitchell</surname>
                            <given-names>S.</given-names>
                        </name>\n<name>
                            <surname>Al-Muderis</surname>
                            <given-names>O.</given-names>
                        </name>\n<name>
                            <surname>Thway</surname>
                            <given-names>K.</given-names>
                        </name>\n<name>
                            <surname>Larkin</surname>
                            <given-names>J.</given-names>
                        </name>\n<name>
                            <surname>Judson</surname>
                            <given-names>I.</given-names>
                        </name>\n</person-group>
                    <article-title>A retrospective study of patients with malignant PEComa receiving
                        treatment with sirolimus or temsirolimus: The Royal Marsden Hospital
                        experience</article-title>
                    <source>Anticancer Res.</source>
                    <year>2014</year>
                    <volume>34</volume>
                    <fpage>3663</fpage>
                    <lpage>3668</lpage>
                    <pub-id pub-id-type="pmid">24982384</pub-id>
                </element-citation>
            </ref>
            <ref id="B11-genes-13-01932">
                <label>11.</label>
                <element-citation publication-type="journal">
                    <person-group person-group-type="author">\n<name>
                            <surname>Bleeker</surname>
                            <given-names>J.S.</given-names>
                        </name>\n<name>
                            <surname>Quevedo</surname>
                            <given-names>J.F.</given-names>
                        </name>\n<name>
                            <surname>Folpe</surname>
                            <given-names>A.L.</given-names>
                        </name>\n</person-group>
                    <article-title>&#x0201c;Malignant&#x0201d; Perivascular Epithelioid Cell
                        Neoplasm: Risk Stratification and Treatment Strategies</article-title>
                    <source>Sarcoma</source>
                    <year>2012</year>
                    <volume>2012</volume>
                    <fpage>12</fpage>
                    <pub-id pub-id-type="doi">10.1155/2012/541626</pub-id>
                    <pub-id pub-id-type="pmid">22619565</pub-id>
                </element-citation>
            </ref>
            <ref id="B12-genes-13-01932">
                <label>12.</label>
                <element-citation publication-type="journal">
                    <person-group person-group-type="author">\n<name>
                            <surname>Italiano</surname>
                            <given-names>A.</given-names>
                        </name>\n<name>
                            <surname>Delcambre</surname>
                            <given-names>C.</given-names>
                        </name>\n<name>
                            <surname>Hostein</surname>
                            <given-names>I.</given-names>
                        </name>\n<name>
                            <surname>Cazeau</surname>
                            <given-names>A.L.</given-names>
                        </name>\n<name>
                            <surname>Marty</surname>
                            <given-names>M.</given-names>
                        </name>\n<name>
                            <surname>Avril</surname>
                            <given-names>A.</given-names>
                        </name>\n<name>
                            <surname>Coindre</surname>
                            <given-names>J.-M.</given-names>
                        </name>\n<name>
                            <surname>Bui</surname>
                            <given-names>B.</given-names>
                        </name>\n</person-group>
                    <article-title>Treatment with the mTOR inhibitor temsirolimus in patients with
                        malignant PEComa</article-title>
                    <source>Ann. Oncol.</source>
                    <year>2010</year>
                    <volume>21</volume>
                    <fpage>1135</fpage>
                    <lpage>1137</lpage>
                    <pub-id pub-id-type="doi">10.1093/annonc/mdq044</pub-id>
                    <pub-id pub-id-type="pmid">20215136</pub-id>
                </element-citation>
            </ref>
            <ref id="B13-genes-13-01932">
                <label>13.</label>
                <element-citation publication-type="journal">
                    <person-group person-group-type="author">\n<name>
                            <surname>Wagner</surname>
                            <given-names>A.J.</given-names>
                        </name>\n<name>
                            <surname>Ravi</surname>
                            <given-names>V.</given-names>
                        </name>\n<name>
                            <surname>Riedel</surname>
                            <given-names>R.F.</given-names>
                        </name>\n<name>
                            <surname>Ganjoo</surname>
                            <given-names>K.</given-names>
                        </name>\n<name>
                            <surname>Van Tine</surname>
                            <given-names>B.A.</given-names>
                        </name>\n<name>
                            <surname>Chugh</surname>
                            <given-names>R.</given-names>
                        </name>\n<name>
                            <surname>Cranmer</surname>
                            <given-names>L.</given-names>
                        </name>\n<name>
                            <surname>Gordon</surname>
                            <given-names>E.M.</given-names>
                        </name>\n<name>
                            <surname>Hornick</surname>
                            <given-names>J.L.</given-names>
                        </name>\n<name>
                            <surname>Du</surname>
                            <given-names>H.</given-names>
                        </name>\n<etal />\n</person-group>
                    <article-title>nab-Sirolimus for Patients with Malignant Perivascular
                        Epithelioid Cell Tumors</article-title>
                    <source>J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.</source>
                    <year>2021</year>
                    <volume>39</volume>
                    <fpage>3660</fpage>
                    <lpage>3670</lpage>
                    <pub-id pub-id-type="doi">10.1200/JCO.21.01728</pub-id>
                    <pub-id pub-id-type="pmid">34637337</pub-id>
                </element-citation>
            </ref>
            <ref id="B14-genes-13-01932">
                <label>14.</label>
                <element-citation publication-type="journal">
                    <person-group person-group-type="author">\n<name>
                            <surname>Sanfilippo</surname>
                            <given-names>R.</given-names>
                        </name>\n<name>
                            <surname>Jones</surname>
                            <given-names>R.L.</given-names>
                        </name>\n<name>
                            <surname>Blay</surname>
                            <given-names>J.-Y.</given-names>
                        </name>\n<name>
                            <surname>Le Cesne</surname>
                            <given-names>A.</given-names>
                        </name>\n<name>
                            <surname>Provenzano</surname>
                            <given-names>S.</given-names>
                        </name>\n<name>
                            <surname>Antoniou</surname>
                            <given-names>G.</given-names>
                        </name>\n<name>
                            <surname>Mir</surname>
                            <given-names>O.</given-names>
                        </name>\n<name>
                            <surname>Fuc&#x000e0;</surname>
                            <given-names>G.</given-names>
                        </name>\n<name>
                            <surname>Fumagalli</surname>
                            <given-names>E.</given-names>
                        </name>\n<name>
                            <surname>Bertulli</surname>
                            <given-names>R.</given-names>
                        </name>\n<etal />\n</person-group>
                    <article-title>Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in
                        Advanced Perivascular Epithelioid Cell Tumors (PEComas)</article-title>
                    <source>Clin. Cancer Res.</source>
                    <year>2019</year>
                    <volume>25</volume>
                    <fpage>5295</fpage>
                    <lpage>5300</lpage>
                    <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-0288</pub-id>
                    <pub-id pub-id-type="pmid">31217199</pub-id>
                </element-citation>
            </ref>
            <ref id="B15-genes-13-01932">
                <label>15.</label>
                <element-citation publication-type="journal">
                    <person-group person-group-type="author">\n<name>
                            <surname>Dabora</surname>
                            <given-names>S.L.</given-names>
                        </name>\n<name>
                            <surname>Franz</surname>
                            <given-names>D.N.</given-names>
                        </name>\n<name>
                            <surname>Ashwal</surname>
                            <given-names>S.</given-names>
                        </name>\n<name>
                            <surname>Sagalowsky</surname>
                            <given-names>A.</given-names>
                        </name>\n<name>
                            <surname>DiMario</surname>
                            <given-names>F.J.</given-names>
                        </name>\n<name>
                            <surname>Miles</surname>
                            <given-names>D.</given-names>
                        </name>\n<name>
                            <surname>Cutler</surname>
                            <given-names>D.</given-names>
                        </name>\n<name>
                            <surname>Krueger</surname>
                            <given-names>D.</given-names>
                        </name>\n<name>
                            <surname>Uppot</surname>
                            <given-names>R.N.</given-names>
                        </name>\n<name>
                            <surname>Rabenou</surname>
                            <given-names>R.</given-names>
                        </name>\n<etal />\n</person-group>
                    <article-title>Multicenter phase 2 trial of sirolimus for tuberous sclerosis:
                        Kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease</article-title>
                    <source>PLoS ONE</source>
                    <year>2011</year>
                    <volume>6</volume>
                    <elocation-id>e23379</elocation-id>
                    <pub-id pub-id-type="doi">10.1371/journal.pone.0023379</pub-id>
                    <pub-id pub-id-type="pmid">21915260</pub-id>
                </element-citation>
            </ref>
            <ref id="B16-genes-13-01932">
                <label>16.</label>
                <element-citation publication-type="journal">
                    <person-group person-group-type="author">\n<name>
                            <surname>Davies</surname>
                            <given-names>D.M.</given-names>
                        </name>\n<name>
                            <surname>de Vries</surname>
                            <given-names>P.J.</given-names>
                        </name>\n<name>
                            <surname>Johnson</surname>
                            <given-names>S.R.</given-names>
                        </name>\n<name>
                            <surname>McCartney</surname>
                            <given-names>D.L.</given-names>
                        </name>\n<name>
                            <surname>Cox</surname>
                            <given-names>J.A.</given-names>
                        </name>\n<name>
                            <surname>Serra</surname>
                            <given-names>A.L.</given-names>
                        </name>\n<name>
                            <surname>Watson</surname>
                            <given-names>P.C.</given-names>
                        </name>\n<name>
                            <surname>Howe</surname>
                            <given-names>C.J.</given-names>
                        </name>\n<name>
                            <surname>Doyle</surname>
                            <given-names>T.</given-names>
                        </name>\n<name>
                            <surname>Pointon</surname>
                            <given-names>K.</given-names>
                        </name>\n<etal />\n</person-group>
                    <article-title>Sirolimus therapy for angiomyolipoma in tuberous sclerosis and
                        sporadic lymphangioleiomyomatosis: A phase 2 trial</article-title>
                    <source>Clin. Cancer Res.</source>
                    <year>2011</year>
                    <volume>17</volume>
                    <fpage>4071</fpage>
                    <lpage>4081</lpage>
                    <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-0445</pub-id>
                    <pub-id pub-id-type="pmid">21525172</pub-id>
                </element-citation>
            </ref>
            <ref id="B17-genes-13-01932">
                <label>17.</label>
                <element-citation publication-type="journal">
                    <person-group person-group-type="author">\n<name>
                            <surname>McCormack</surname>
                            <given-names>F.X.</given-names>
                        </name>\n<name>
                            <surname>Inoue</surname>
                            <given-names>Y.</given-names>
                        </name>\n<name>
                            <surname>Moss</surname>
                            <given-names>J.</given-names>
                        </name>\n<name>
                            <surname>Singer</surname>
                            <given-names>L.G.</given-names>
                        </name>\n<name>
                            <surname>Strange</surname>
                            <given-names>C.</given-names>
                        </name>\n<name>
                            <surname>Nakata</surname>
                            <given-names>K.</given-names>
                        </name>\n<name>
                            <surname>Barker</surname>
                            <given-names>A.F.</given-names>
                        </name>\n<name>
                            <surname>Chapman</surname>
                            <given-names>J.T.</given-names>
                        </name>\n<name>
                            <surname>Brantly</surname>
                            <given-names>M.L.</given-names>
                        </name>\n<name>
                            <surname>Stocks</surname>
                            <given-names>J.M.</given-names>
                        </name>\n<etal />
                        \n</person-group>
                    <article-title>Efficacy and safety of sirolimus in lymphangioleiomyomatosis</article-title>
                    <source>N. Engl. J. Med.</source>
                    <year>2011</year>
                    <volume>364</volume>
                    <fpage>1595</fpage>
                    <lpage>1606</lpage>
                    <pub-id pub-id-type="doi">10.1056/NEJMoa1100391</pub-id>
                    <pub-id pub-id-type="pmid">21410393</pub-id>
                </element-citation>
            </ref>
            <ref id="B18-genes-13-01932">
                <label>18.</label>
                <element-citation publication-type="journal">
                    <person-group person-group-type="author">\n<name>
                            <surname>Folpe</surname>
                            <given-names>A.L.</given-names>
                        </name>\n<name>
                            <surname>Mentzel</surname>
                            <given-names>T.</given-names>
                        </name>\n<name>
                            <surname>Lehr</surname>
                            <given-names>H.-A.</given-names>
                        </name>\n<name>
                            <surname>Fisher</surname>
                            <given-names>C.</given-names>
                        </name>\n<name>
                            <surname>Balzer</surname>
                            <given-names>B.L.</given-names>
                        </name>\n<name>
                            <surname>Weiss</surname>
                            <given-names>S.W.</given-names>
                        </name>\n</person-group>
                    <article-title>Perivascular epithelioid cell neoplasms of soft tissue and
                        gynecologic origin: A clinicopathologic study of 26 cases and review of the
                        literature</article-title>
                    <source>Am. J. Surg. Pathol.</source>
                    <year>2005</year>
                    <volume>29</volume>
                    <fpage>1558</fpage>
                    <lpage>1575</lpage>
                    <pub-id pub-id-type="doi">10.1097/01.pas.0000173232.22117.37</pub-id>
                    <pub-id pub-id-type="pmid">16327428</pub-id>
                </element-citation>
            </ref>
            <ref id="B19-genes-13-01932">
                <label>19.</label>
                <element-citation publication-type="journal">
                    <person-group person-group-type="author">\n<name>
                            <surname>Schoolmeester</surname>
                            <given-names>J.K.</given-names>
                        </name>\n<name>
                            <surname>Dao</surname>
                            <given-names>L.N.</given-names>
                        </name>\n<name>
                            <surname>Sukov</surname>
                            <given-names>W.R.</given-names>
                        </name>\n<name>
                            <surname>Wang</surname>
                            <given-names>L.</given-names>
                        </name>\n<name>
                            <surname>Park</surname>
                            <given-names>K.J.</given-names>
                        </name>\n<name>
                            <surname>Murali</surname>
                            <given-names>R.</given-names>
                        </name>\n<name>
                            <surname>Hameed</surname>
                            <given-names>M.R.</given-names>
                        </name>\n<name>
                            <surname>Soslow</surname>
                            <given-names>R.A.</given-names>
                        </name>\n</person-group>
                    <article-title>TFE3 translocation-associated perivascular epithelioid cell
                        neoplasm (PEComa) of the gynecologic tract: Morphology, immunophenotype,
                        differential diagnosis</article-title>
                    <source>Am. J. Surg. Pathol.</source>
                    <year>2015</year>
                    <volume>39</volume>
                    <fpage>394</fpage>
                    <lpage>404</lpage>
                    <pub-id pub-id-type="doi">10.1097/PAS.0000000000000349</pub-id>
                    <pub-id pub-id-type="pmid">25517951</pub-id>
                </element-citation>
            </ref>
            <ref id="B20-genes-13-01932">
                <label>20.</label>
                <element-citation publication-type="journal">
                    <person-group person-group-type="author">\n<name>
                            <surname>Cazzato</surname>
                            <given-names>G.</given-names>
                        </name>\n<name>
                            <surname>Colagrande</surname>
                            <given-names>A.</given-names>
                        </name>\n<name>
                            <surname>Lospalluti</surname>
                            <given-names>L.</given-names>
                        </name>\n<name>
                            <surname>Pacello</surname>
                            <given-names>L.</given-names>
                        </name>\n<name>
                            <surname>Lettini</surname>
                            <given-names>T.</given-names>
                        </name>\n<name>
                            <surname>Arezzo</surname>
                            <given-names>F.</given-names>
                        </name>\n<name>
                            <surname>Loizzi</surname>
                            <given-names>V.</given-names>
                        </name>\n<name>
                            <surname>Lupo</surname>
                            <given-names>C.</given-names>
                        </name>\n<name>
                            <surname>Casatta</surname>
                            <given-names>N.</given-names>
                        </name>\n<name>
                            <surname>Cormio</surname>
                            <given-names>G.</given-names>
                        </name>\n<etal />\n</person-group>
                    <article-title>Primitive Cutaneous (P)erivascular (E)pithelioid (C)ell Tumour
                        (PEComa): A New Case Report of a Rare Cutaneous Tumor</article-title>
                    <source>Genes</source>
                    <year>2022</year>
                    <volume>13</volume>
                    <elocation-id>1153</elocation-id>
                    <pub-id pub-id-type="doi">10.3390/genes13071153</pub-id>
                    <pub-id pub-id-type="pmid">35885936</pub-id>
                </element-citation>
            </ref>
        </ref-list>
    </back>
    <floats-group>
        <fig position="float" id="genes-13-01932-f001">
            <label>Figure 1</label>
            <caption>
                <p>OS of patients with <italic toggle="yes">TSC-1</italic> versus <italic
                        toggle="yes">TSC-2</italic> mutated tumors. Two patients had <italic
                        toggle="yes">TSC-1</italic> mutations and 12 patients had <italic
                        toggle="yes">TSC-2</italic> mutations. Four of the <italic toggle="yes">
                    TSC-2</italic> mutated tumors were treated with local resection without systemic
                    therapy without recurrence. Only one of the <italic toggle="yes">TSC-1</italic>
                    mutated tumors received mTOR inhibition. Abbreviations: OS, overall survival;
                    TSC, tuberous sclerosis complex.</p>
            </caption>
            <graphic xlink:href="genes-13-01932-g001" position="float" />
        </fig>
        <fig position="float" id="genes-13-01932-f002">
            <label>Figure 2</label>
            <caption>
                <p>OS of the group of patients with <italic toggle="yes">TSC-1</italic> and <italic
                        toggle="yes">-2</italic> mutated tumors versus other mutations. Patients who
                    did not have genetic testing sent out were excluded from this analysis.
                    Abbreviations: OS, overall survival; TSC, tuberous sclerosis complex.</p>
            </caption>
            <graphic xlink:href="genes-13-01932-g002" position="float" />
        </fig>
        <fig position="float" id="genes-13-01932-f003">
            <label>Figure 3</label>
            <caption>
                <p>Progression-free survival based on first-line systemic therapy censored at 12
                    months. Patients included in this analysis underwent systemic therapy for their
                    PEComa (n = 22). Fourteen patients had first-line therapy with mTOR inhibition.
                    Only two patients did not meet criteria for malignant PEComa; they had initial
                    resection with local recurrence requiring systemic therapy. Abbreviations: PFS1,
                    progression-free survival of first-line therapy; mTORi, mTOR inhibition.</p>
            </caption>
            <graphic xlink:href="genes-13-01932-g003" position="float" />
        </fig>
        <table-wrap position="float" id="genes-13-01932-t001">
            <object-id pub-id-type="pii">genes-13-01932-t001_Table 1</object-id>
            <label>Table 1</label>
            <caption>
                <p>Baseline characteristics. * Some cases had multiple mutations.</p>
            </caption>
            <table frame="hsides" rules="groups">
                <thead>
                    <tr>
                        <th align="center" valign="middle"
                            style="border-top:solid thin;border-bottom:solid thin" rowspan="1"
                            colspan="1">Patient Characteristics</th>
                        <th align="center" valign="middle"
                            style="border-top:solid thin;border-bottom:solid thin" rowspan="1"
                            colspan="1"><italic toggle="yes">N</italic> = 49 (%)</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n<bold>Sex</bold>
                            \n</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">Male</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">14 (28)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">Female</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">36 (72)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n<bold>Age at
                            Diagnosis (years)</bold>\n</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">54
                            (31&#x02013;78) *</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n<bold>Tumor
                            Subtype</bold>\n</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">Angiomyolipoma</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">11 (22)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">PEComa</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">34 (68)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n<bold>Primary
                            Tumor Location</bold>\n</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">GI Tract</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">9 (18)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">Soft Tissue</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">5 (10)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">Liver</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">1 (2)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">
                            Kidney/Retroperitoneum</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">13 (26)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">Uterus</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">12 (24)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">Unknown</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">9 (20)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n<bold>Metastases
                            at Presentation</bold>\n</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">5 (10)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n<bold>Local
                            Recurrence</bold>\n</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">16 (32)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n<bold>Grade</bold>
                            \n</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">High</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">18 (36)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">Low</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">1 (2)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">Malignant PEComa</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">27 (55)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n<bold>Surgical
                            Resection</bold>\n</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">47 (94)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n<bold>Treated
                            with Systemic Therapy</bold>\n</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">22 (44)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n<bold>Mutational
                            Status Known *</bold>\n</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">20 (40)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n<italic
                                toggle="yes">TSC-1</italic>\n</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">2 (4)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n<italic
                                toggle="yes">TSC-2</italic>\n</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">12 (24)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1"><italic
                                toggle="yes">TFE-3</italic> Translocation</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">9 (18)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1"><italic
                                toggle="yes">TP53</italic> Mutation</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">9 (18)</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" style="border-bottom:solid thin"
                            rowspan="1" colspan="1"><italic toggle="yes">RB1</italic> Mutation</td>
                        <td align="center" valign="middle" style="border-bottom:solid thin"
                            rowspan="1" colspan="1">3 (6)</td>
                    </tr>
                </tbody>
            </table>
        </table-wrap>
        <table-wrap position="float" id="genes-13-01932-t002">
            <object-id pub-id-type="pii">genes-13-01932-t002_Table 2</object-id>
            <label>Table 2</label>
            <caption>
                <p>Overall response rate and clinical benefit rate.</p>
            </caption>
            <table frame="hsides" rules="groups">
                <thead>
                    <tr>
                        <th align="center" valign="middle"
                            style="border-top:solid thin;border-bottom:solid thin" rowspan="1"
                            colspan="1">Mutation</th>
                        <th align="center" valign="middle"
                            style="border-top:solid thin;border-bottom:solid thin" rowspan="1"
                            colspan="1">First-Line Therapy</th>
                        <th align="center" valign="middle"
                            style="border-top:solid thin;border-bottom:solid thin" rowspan="1"
                            colspan="1"><italic toggle="yes">N</italic> = 18</th>
                        <th align="center" valign="middle"
                            style="border-top:solid thin;border-bottom:solid thin" rowspan="1"
                            colspan="1">ORR (%)</th>
                        <th align="center" valign="middle"
                            style="border-top:solid thin;border-bottom:solid thin" rowspan="1"
                            colspan="1">CBR (%)</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td rowspan="3" align="center" valign="middle"
                            style="border-bottom:solid thin" colspan="1">\n<italic toggle="yes">TSC-1
                            or -2</italic>\n</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">mTORi</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">8</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">25</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">75</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">Anthracycline</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">0</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" style="border-bottom:solid thin"
                            rowspan="1" colspan="1">Other</td>
                        <td align="center" valign="middle" style="border-bottom:solid thin"
                            rowspan="1" colspan="1">1 *</td>
                        <td align="center" valign="middle" style="border-bottom:solid thin"
                            rowspan="1" colspan="1">100</td>
                        <td align="center" valign="middle" style="border-bottom:solid thin"
                            rowspan="1" colspan="1">100</td>
                    </tr>
                    <tr>
                        <td rowspan="3" align="center" valign="middle"
                            style="border-bottom:solid thin" colspan="1">Other</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">mTORi</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">6</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">33.3</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">66.7</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" rowspan="1" colspan="1">Anthracycline</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">0</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n</td>
                        <td align="center" valign="middle" rowspan="1" colspan="1">\n</td>
                    </tr>
                    <tr>
                        <td align="center" valign="middle" style="border-bottom:solid thin"
                            rowspan="1" colspan="1">Other</td>
                        <td align="center" valign="middle" style="border-bottom:solid thin"
                            rowspan="1" colspan="1">3 **</td>
                        <td align="center" valign="middle" style="border-bottom:solid thin"
                            rowspan="1" colspan="1">0</td>
                        <td align="center" valign="middle" style="border-bottom:solid thin"
                            rowspan="1" colspan="1">66.7</td>
                    </tr>
                </tbody>
            </table>
            <table-wrap-foot>
                <fn>
                    <p>This table compares the mutational status and response to different
                        therapies. The column &#x0201c;<italic toggle="yes">N</italic>&#x0201d; is
                        the number of patients who had the mutation and underwent the first-line
                        therapy mentioned. Abbreviations: ORR, overall response rate; CBR, clinical
                        benefit response; mTORi, mTOR inhibition. * The patient was treated with
                        pembrolizumab and had a partial response to therapy with time to progression
                        of 20.22 months. ** Two patients were treated with taxanes, and one was
                        treated with arimidex since the tumor was positive for estrogen receptor.</p>
                </fn>
            </table-wrap-foot>
        </table-wrap>
    </floats-group>
</article>